RxDoctor Payments Data

Catherine Obin

Nurse Practitioner · Wareham, MANPI 1841286739

Payments from drug & device makers

$2,513in general payments, 2019–2025

Across 31 payments — averaging $81.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$317
  • Johnson & Johnson$305
  • Otsuka America Pharmaceutical, Inc.$250
  • AbbVie$227
  • Phathom Pharmaceuticals, Inc.$157
  • Boehringer Ingelheim$138
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$2,46398%
  • Other$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,513 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$102,406
Medicare patients
297
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide35$41,318
OzempicSemaglutide23$28,033
EliquisApixaban31$25,328
JardianceEmpagliflozin30$22,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$14,540
Breo ElliptaFluticasone/Vilanterol18$8,731
Advair HfaFluticasone Propion/Salmeterol12$5,670
Varenicline Tartrate14$5,383
Incruse ElliptaUmeclidinium Bromide11$3,861
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,272
Rosuvastatin Calcium104$3,265
Metoprolol Succinate103$2,479
Omeprazole165$2,377
SynthroidLevothyroxine Sodium30$2,182
Atorvastatin Calcium137$1,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$125$41,31835 claims
Novo NordiskOzempic$134$28,03323 claims
Boehringer IngelheimJardiance$138$22,17630 claims
AbbVieSynthroid$227$2,18230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Wareham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →